Trials / Unknown
UnknownNCT03113708
The Effect of Heparinization Due to LBW
The Effect of Heparinization Due to LBW in Cardiac Surgery
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- Sponsor
- Adiyaman University Research Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
High dose heparin regimens are required in cardiac surgery under cardiopulmonary bypass (CPB) and this may increase postoperative bleeding. The aim of this study is to evaluate the effect of heparin dose calculated according to lean body weight on intraoperative and postoperative bleeding.
Detailed description
Patients with preoperative demographic data such as age, gender, body weight, height, and additional disease, medications, previous surgery, preoperative Htc / Hb values were recorded in the operation room without medical premedication. Standard anesthesia induction was performed after arterial cannulation and peripheral venous route. Patients were randomly divided into two groups: 400 IU heparin / kg (Group I) and 400 IU heparin / kg (Group II) according to actual body weight and lean body weight respectively before CPB. Before and after heparin administration, CPB entry and ACT (Activated Clotting Time) values were counted every 30 minutes, after CPB exit and protamine. In both groups, supplemental heparin was administered when there was a failure to reach the pre-CPB target ACT value of 400 sec. Hemodynamic data and transfusion requirements were recorded during the operation. Patient's intraoperative CPB and crossover times, postoperative drainage volume and blood transfusion requirement were recorded.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Heparin Sodium | Heparinisation 2-4 mg/kg will be done according to actual body weight or lean body weight. |
Timeline
- Start date
- 2017-04-30
- Primary completion
- 2017-05-20
- Completion
- 2017-06-20
- First posted
- 2017-04-13
- Last updated
- 2017-04-14
Source: ClinicalTrials.gov record NCT03113708. Inclusion in this directory is not an endorsement.